

Niclosamide encapsulated polymeric nanocarriers for targeted cancer therapy

Nishant Kumar Jain,^a Prabhuraj R S,^b M C Bavya,^a Rajendra Prasad,^a Rajdip Bandyopadhyaya,^c V.G.M.Naidu,^d and Rohit Srivastava*^a

^aDepartment of Biosciences and Bioengineering, Indian Institute of Technology Bombay (IIT-B), Powai, Mumbai, 400076, India

^bCentre for Research in Nanotechnology and Science, Indian Institute of Technology Bombay (IIT-B), Powai, Mumbai, 400076, India

^cDepartment of chemical engineering, Indian Institute of Technology Bombay (IIT-B), Powai, Mumbai, 400076, India

^dDepartment of **Pharmacology & Toxicology**, National Institute of Pharmaceutical Education and Research (NIPER), Guwahati, Assam, 781125, India

Corresponding Author

*Email:

Rohit Srivastava: rsrivasta@iitb.ac.in




Figure S1: Zeta analysis of (A) PLGA NP, (B) [(PLGA NP)HA], (C) NIC-PLGA NP and (D) [(NIC-PLGA NP)HA]




Figure S2: Particle size analysis of (A) PLGA NP, (B) [(PLGA NP)HA], (C) NIC-PLGA NP and (D) [(NIC-PLGA NP)HA]




Figure S3: In-vitro biocompatibility of blank PLGA NP and [(PLGA NP)HA] in A) MDA-MB-231 cells and B) L929 Cells

Table S1: DLS, zeta potential and entrapment efficiency of the prepared formulations

Formulation	DLS (nm)	PDI	Zeta potential (mV)	Entrapment Efficiency (%)
PLGA NP	159.9±4.3	0.130	-6.47±5.99	-
[(PLGA NP)HA]	191.6±1.5	0.150	-16.3±4.64	-
NIC-PLGA NP	178.2±4.0	0.108	-11.2±5.02	86.18±0.73
[(NIC-PLGA NP)HA]	201.8±3.6	0.164	-24.9±7.21	79.19±0.16